Literature DB >> 15703497

Cotton rat tumor model for the evaluation of oncolytic adenoviruses.

Karoly Toth1, Jacqueline F Spencer, Ann E Tollefson, Mohan Kuppuswamy, Konstantin Doronin, Drew L Lichtenstein, Marie C La Regina, Gregory A Prince, William S M Wold.   

Abstract

Oncolytic human adenovirus (Ad) vectors exert their antitumor effect by replicating in and lysing tumor cells. These vectors are commonly evaluated in immunodeficient mice bearing human tumor xenografts. However, this model suffers because the mice are immunodeficient and are not permissive for human Ads. We have developed a cotton rat model to test the selectivity, immunogenicity, and efficacy of oncolytic Ad vectors. The cotton rat is a rodent species that is semipermissive for human Ads. We show that the cotton cancer rat cell line LCRT supports the replication of human Ad in tissue culture and that the cells are destroyed on virus replication. When injected subcutaneously, LCRT cells formed tumors in immunocompetent cotton rats, and the growth of these tumors was delayed by the injection of an oncolytic Ad vector. Replication of the Ad vector in the tumor was demonstrated by sampling tumor tissue and isolating infectious virus particles at various times after intratumoral injection of the virus. We propose that the cotton rat can be used as an animal model to evaluate oncolytic Ad vectors.

Entities:  

Mesh:

Year:  2005        PMID: 15703497     DOI: 10.1089/hum.2005.16.139

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  30 in total

Review 1.  Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  Alternatives to retroorbital blood collection in hispid cotton rats (Sigmodon hispidus).

Authors:  Jessica D Ayers; Paul A Rota; Marcus L Collins; Clifton P Drew
Journal:  J Am Assoc Lab Anim Sci       Date:  2012-03       Impact factor: 1.232

Review 3.  Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism.

Authors:  J Michael Mathis; Phoebe L Stewart; Zheng B Zhu; David T Curiel
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

4.  A fully replication-competent adenovirus vector with enhanced oncolytic properties.

Authors:  K Toth; M Kuppuswamy; E V Shashkova; J F Spencer; W S M Wold
Journal:  Cancer Gene Ther       Date:  2010-07-02       Impact factor: 5.987

5.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  Handling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.

Authors:  Breanne Cuddington; Meghan Verschoor; Karen Mossman
Journal:  J Vis Exp       Date:  2014-11-24       Impact factor: 1.355

7.  Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Authors:  T Cherry; S L Longo; Z Tovar-Spinoza; D E Post
Journal:  Gene Ther       Date:  2010-07-22       Impact factor: 5.250

Review 8.  Prospects for oral replicating adenovirus-vectored vaccines.

Authors:  Cailin Deal; Andrew Pekosz; Gary Ketner
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

9.  Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus.

Authors:  Jason C Steel; Brian J Morrison; Poonam Mannan; Mones S Abu-Asab; Oliver Wildner; Brian K Miles; Kevin C Yim; Vijay Ramanan; Gregory A Prince; John C Morris
Journal:  Virology       Date:  2007-08-28       Impact factor: 3.616

10.  Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model.

Authors:  Karoly Toth; Jacqueline F Spencer; Debanjan Dhar; John E Sagartz; R Mark L Buller; George R Painter; William S M Wold
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.